An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A recent report says that people using semaglutide — the drug in popular weight-loss shots like Ozempic and Wegovy — tend to feel less hungry at first, but those feelings of hunger slowly come back over time. The piece summarizes observations from clinicians and some research suggesting the appetite-suppressing effect weakens during continued use. It’s a reminder that the drug’s initial impact on appetite may not stay as strong forever. Semaglutide is a man-made version of a hormone your gut makes after you eat. That hormone talks to your brain to help you feel full and to slow how quickly your stomach empties. In people with diabetes or those trying to lose weight, semaglutide helps lower blood sugar and reduces appetite. Doctors give it as a weekly injection and it’s become well-known because many people on it report eating less and losing weight. What the report actually describes is mostly clinical observations and references to studies showing that hunger suppression is most obvious early in treatment, then less so later. Some controlled trials have shown that people on semaglutide eat fewer calories and lose weight compared with placebo. But the specific note about hunger returning is based on longer-term follow-ups and patient reports, not a single definitive experiment that proves why the effect fades. The size of the change varies: some people regain a good deal of appetite, others only a little. The report doesn’t claim that semaglutide stops working entirely, just that the strong early reduction in hunger can weaken. This matters because many people use semaglutide precisely to curb appetite and make dieting easier. If hunger returns, it might make weight maintenance harder and could lead to frustration or stopping the medication. For clinicians and patients, it highlights the importance of planning for long-term strategies — such as behavioral changes, diet tweaks, or other supports — rather than expecting the drug alone to permanently eliminate hunger. People considering semaglutide should know it may be a powerful early aid but not necessarily a forever fix for appetite. There are some important caveats. Semaglutide is a prescription medication and has known side effects like nausea, diarrhea, or constipation, and more serious but rarer risks. The observation that hunger returns doesn’t mean everyone will experience it, and the degree of return varies. The report doesn’t provide new regulatory findings or say the drug is unsafe; it is an observation about effectiveness over time. Anyone thinking about starting or stopping semaglutide should talk with their doctor, especially people who are pregnant, breastfeeding, or have certain medical conditions. Bottom line: Semaglutide often cuts appetite strongly at first, but that reduced hunger can ease over time, so long-term plans beyond the drug alone are important.
Source: Optometry Advisor